1. Home
  2. Live Updates
  3. Carolina urologic research center

Live Breaking News & Updates on Carolina urologic research center

Stay informed with the latest breaking news from Carolina urologic research center on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Carolina urologic research center and stay connected to the pulse of your community

Dr Shore on Key Clinical Trial Data in Biochemically Recurrent Prostate Cancer

Neal Shore, MD, FACS, discusses findings from clinical trials in patients with prostate cancer who experience biochemical recurrence.

Carolina-urologic-research-center , Neal-shore , Medical-officer , Genesiscare-united-states , Atlantic-urology , Uspcc , D , Acs , Biochemical-recurrence , Prostate-cancer , Phase-3-embark-trial-nct02319837

Dr Shore on the Background and Outcomes of the EMBARK Trial in nmCSPC

Neal Shore, MD, FACS, discusses the phase 3 EMBARK study of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

United-states , Carolina-urologic-research-center , Neal-shore , Genesiscare-united-states , Prostate-cancer , Onclive-tv ,

Post-Hoc Analysis Confirms Consistent Clinical Benefit With Olaparib Plus Abiraterone in HRR-Mutated mCRPC

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.

Boston , Massachusetts , United-states , Bristol-myers-squibb , Bristol-myers-squibb-sanofi , Medivation-astellas , Immunitybio-incyte , Merck-serono , Nonagen-bioscience , Astellas-pharma , Jiangsu-yahong-meditech , Pfizer

Shore Highlights Ongoing Efforts With PARP Inhibitors, Radioligand Therapy in Prostate Cancer

Neal Shore, MD, FACS, discusses attempts to expand the current prostate cancer armamentarium through the development of novel, targeted therapies, which he notes are vital for moving the paradigm forward and ultimately improving patient outcomes.

Myrtle-beach , South-carolina , United-states , Carolina-urologic-research-center , Neal-shore , Genesiscare-united-states , 177lu-psma-617 , Prostate-cancer , D , Acs , Mcrpc

Enzalutamide Intensifies the Activity of ADT Monotherapy and Expands Limited nmCSPC Treatment Armamentarium

Neal Shore, MD, FACS, highlights the efficacy data from the EMBARK study, toxicities observed with enzalutamide alone or in combination with a LHRH agonist, and the significance of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.

Myrtle-beach , South-carolina , United-states , Carolina-urologic-research-center , Neal-shore , Genesiscare-united-states , New-england-journal , Enzalutamide- , Nonmetastatic-castration-sensitive-prostate-cancer- , Nmcspc , D

Xtandi Gains Approval for Nonmetastatic Castration-Sensitive Prostate Cancer

The FDA has approved Xtandi (enzalutamide) for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with high-risk BCR.

Carolina-urologic-research-center , Drug-administration , New-drug-application , Neal-shore , Chief-medical-officer , Strategic-innovation , Genesiscare-united-states ,

Xtandi Gains Approval for Nonmetastatic Castration-Sensitive Prostate Cancer

The FDA has approved Xtandi (enzalutamide) for the treatment of patients with nonmetastatic castration-sensitive prostate cancer with high-risk BCR.

Drug-administration , Carolina-urologic-research-center , New-drug-application , Neal-shore , Chief-medical-officer , Strategic-innovation , Genesiscare-united-states ,

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the companies...

Japan , Canada , Tokyo , United-states , American , America , Chris-boshoff , Naoki-okamura , Ahsan-arozullah , Courtney-bugler , Head-of-oncology-development , American-urological-association-annual-meeting

U.S. FDA Approves Pfizer, Astellas' XTANDI for Early Prostate Cancer

U.S. FDA Approves Pfizer, Astellas' XTANDI for Early Prostate Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United-states , Canada , American , America , Ahsan-arozullah , Naoki-okamura , Courtney-bugler , Chris-boshoff , Head-of-oncology-development , Oncology-research , Drug-administration , Astellas-pharma-inc

Pfizer (PFE) and Astellas' XTANDI Approved by FDA in Earlier Prostate Cancer Treatment Setting

Pfizer (PFE) and Astellas' XTANDI Approved by FDA in Earlier Prostate Cancer Treatment Setting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Ahsan-arozullah , Chris-boshoff , Courtney-bugler , Head-of-oncology-development , Oncology-research , American-urological-association-annual-meeting , Drug-administration , Astellas-pharma-inc , Pfizer-inc , European-medicines-agency